PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on: October 15,2023

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on:October 15,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on: October 17,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on:October 17,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on: October 12,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on:October 12,2023

Study uncovers the role of NETO2-mediated regulation in melanoma progression

by Frontiers JournalsCredit:Frontiers of Medicine(2023). DOI: 10.1007/s11684-022-0935-0Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, Ch

Updated on: August 27,2024

Study uncovers the role of NETO2-mediated regulation in melanoma progression

by Frontiers JournalsCredit:Frontiers of Medicine(2023). DOI: 10.1007/s11684-022-0935-0Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, Ch

Updated on:August 27,2024

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on: December 20,2023

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on:December 20,2023

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on: December 17,2023

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on:December 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on: October 17,2023

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on:October 17,2023

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

Updated on: December 19,2023

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

Updated on:December 19,2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on: October 23,2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on:October 23,2023

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on: December 22,2023

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on:December 22,2023